The U.S. Food and Drug Administration (FDA) has approved Benlysta® to treat lupus nephritis (lupus-related kidney disease) in adults. The approval is for both the intravenous and subcutaneous ...

Short-term observational data support belimumab as a safe therapeutic option in patients with lupus nephritis, who are at increased risk of cancer. Over the short term, overall cancer risk may be ...

Spherix Global Insights finds rising biologic adoption across specialties, with most physicians signaling intent to adopt CLE-specific pipeline therapies earlier in treatment.Exton, PA, March 17, 2026 ...

Exton, PA, March 06, 2026 (GLOBE NEWSWIRE) -- New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as ...

Benlysta is an immunosuppressant medication that can lower the amount of antibodies your immune system produces. This makes it effective in managing different forms of lupus. Benlysta works by ...

The odds of dialysis, ESRD, and renal transplant were significantly lower in the belimumab group compared with the MMF group. Belimumab, a B-lymphocyte stimulator-specific inhibitor, appears to be ...

In patients with proliferative lupus nephritis, belimumab combined with standard therapy improved renal response rates, reduced glucocorticoid use over 12 months, and showed a favorable safety profile ...

Exton, PA, March 06, 2026 (GLOBE NEWSWIRE) -- New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as ...